三元生物(301206) - 2023 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2023 was ¥116,276,458.04, a decrease of 57.35% compared to ¥272,598,107.02 in the same period last year[4] - Net profit attributable to shareholders was ¥7,808,194.59, down 87.56% from ¥62,765,994.16 year-on-year[4] - Basic and diluted earnings per share fell by 92.16%, from ¥0.51 to ¥0.04[4] - The total operating revenue for Q1 2023 was ¥116,276,458.04, a decrease of 57.3% compared to ¥272,598,107.02 in the same period last year[25] - The net profit for Q1 2023 was ¥7,808,194.59, a decline of 87.5% compared to ¥62,765,994.16 in Q1 2022[27] Cash Flow - The net cash flow from operating activities decreased by 87.17%, from ¥20,443,976.73 to ¥2,622,930.65[4] - The net cash flow from operating activities for the first quarter was ¥2,622,930.65, a decrease of 87.2% compared to ¥20,443,976.73 in the previous period[31] - Total cash inflow from operating activities was ¥143,143,501.00, down from ¥312,922,891.80 in the previous period[30] - Cash received from sales of goods and services was ¥125,411,624.65, a decline from ¥285,616,286.62 in the previous period[30] - The ending balance of cash and cash equivalents was ¥142,378,891.60, down from ¥267,134,010.23 in the previous period[31] Assets and Liabilities - Total assets at the end of the reporting period were ¥4,858,759,156.00, a slight decrease of 0.23% from the previous year[4] - The total liabilities for Q1 2023 were ¥230,174,915.00, a decrease from ¥249,143,294.88 in the same period last year[24] - The company's long-term equity investments amounted to ¥59,706,991.87, a slight decrease from ¥60,156,008.48 in the previous year[24] Income and Expenses - The total operating costs for Q1 2023 were ¥135,685,668.54, down 37.1% from ¥215,835,919.52 in Q1 2022[25] - Research and development expenses for Q1 2023 were ¥11,788,523.18, an increase of 15.4% compared to ¥10,219,983.55 in Q1 2022[25] - Other income increased by 1,413.01%, mainly due to government subsidies received during the reporting period[8] - The company reported a significant increase in other income to ¥506,858.66 from ¥33,500.01 in the previous year[27] Shareholder Information - The total number of shares held by major shareholders includes 12,852,000 shares by Liu Xi'an and 5,399,970 shares by Shandong Kexin Venture Capital Co., Ltd[11] - The company reported a total of 92,946,000 restricted shares held by Nie Zaijian, with the release date set for August 10, 2025[13] - The company has 24,780,000 shares released from restrictions as of February 10, 2023, indicating a significant liquidity event for shareholders[14] - The total number of shares held by the top 10 unrestricted shareholders includes 2,681,475 shares by Wang Shen and 2,653,995 shares by Wang Meihua[11] Fund Management - The company plans to use RMB 790 million of the raised funds to permanently supplement its working capital starting from March 2, 2023[16] - The company approved the use of up to RMB 2.4 billion of temporarily idle raised funds for cash management, effective for 12 months from the approval date[17] - The company intends to use up to RMB 2.2 billion of temporarily idle self-owned funds for cash management, also effective for 12 months from the approval date[18] Investment Activities - Total cash inflow from investment activities was ¥10,416,708.33, significantly up from ¥477,900.00 in the previous period[31] - The net cash flow from investment activities was -¥328,183,999.71, compared to -¥3,562,704,045.45 in the previous period, indicating a reduction in cash outflow[31] Share Reduction Plans - The company’s major shareholder, Shandong Luxin Qisheng Investment Management Co., plans to reduce its holdings by up to 12.14 million shares, representing 6% of the total share capital[20] - The chairman of the supervisory board, Cui Zhenqian, completed a share reduction plan, selling up to 170,625 shares, which is 0.0843% of the total share capital[19] Other Information - The company did not engage in any financing activities during the reporting period, resulting in a 100% decrease in cash flow from financing activities[8] - The company did not report any new product developments or market expansions during this quarter[32]